May 02, 2018
1 min read

Pediatric cancer specialists join NYU Langone

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Elizabeth A. Raetz
Theodore P. Nicolaides

Two leaders in pediatric cancer have joined Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center.

Elizabeth A. Raetz, MD, will serve as director of the division of pediatric hematology and oncology, as well as medical director of Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders.

Theodore P. Nicolaides, MD, will serve as director of pediatric neuro-oncology.

Raetz previously served as a faculty member at NYU Langone. She most recently as been at University of Utah and Primary Children’s Hospital, where she served as clinical professor in the department of pediatrics, director of the leukemia program and investigator at Huntsman Cancer Institute.

Her research focuses on strategies to improve outcomes for patients with acute lymphoblastic leukemia, specifically children with recurrent and high-risk forms of the disease.

Nicolaides, joins NYU Langone from University of California, San Francisco, where he served as assistant professor in residence in the division of hematology/oncology in the department of pediatrics and director of the UCSF Brain Tumor Research Center Preclinical Core.

His research focuses on novel treatment approaches for individuals with brain cancer that help them preserve mental capacities and enable normal development.

“[Raetz and Nicolaides] have strong backgrounds in cancer research, which they bring in addition to their leadership roles,” Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center, said in a press release. “Their work at Hassenfeld Children’s Hospital and Perlmutter Cancer Center will help to advance the field of pediatric cancer care, improving the standard of care and the quality of life of our patients.”